Antenatal therapy
| Treatment . | Diagnosis . | Stage at relapse . | GA at relapse (wk) . | GA when therapy started (wk) . | Delivery (wk) . |
|---|---|---|---|---|---|
| Modified ESHAP; then nivolumab | cHL | IIIB | 12 | 20 and 25, respectively | 38∗ |
| DHAP, IGEV | cHL | NA | 20 | 25 | 36† |
| R-ICE | DLBCL | IIIA | 25 | 25 | 26† |
| ESHAP | PTCL NOS | II | 30 | 31 | 37∗ |
| Modified ESHAP (lowered cytarabine) | ALK negative ALCL | IIIA | 30 | 32 | 36† |
| Treatment . | Diagnosis . | Stage at relapse . | GA at relapse (wk) . | GA when therapy started (wk) . | Delivery (wk) . |
|---|---|---|---|---|---|
| Modified ESHAP; then nivolumab | cHL | IIIB | 12 | 20 and 25, respectively | 38∗ |
| DHAP, IGEV | cHL | NA | 20 | 25 | 36† |
| R-ICE | DLBCL | IIIA | 25 | 25 | 26† |
| ESHAP | PTCL NOS | II | 30 | 31 | 37∗ |
| Modified ESHAP (lowered cytarabine) | ALK negative ALCL | IIIA | 30 | 32 | 36† |
ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma kinase; DLBCL, diffuse large B-cell lymphoma; DHAP, dexamethasone, high dose cytarabine, cisplatin; ESHAP, etoposide, methylprednisolone, cytarabine, cisplatin; GA, gestational age; IGEV, ifosfamide + gemcitabine + vinorelbine; NA, not available; PTCL NOS, peripheral T-cell lymphoma not otherwise specified; R-ICE: rituximab, ifosfamide, carboplatin, etoposide.
Clinician-initiated delivery.
Spontaneous delivery.